Better Coronavirus Stock: Thermo Fisher Scientific or Roche?
Despite a painful market correction in March and a bevy of weak earnings reports stemming from the COVID-19 pandemic across the market, healthcare stocks are flourishing like never before. Between companies developing therapeutics or vaccines and companies offering diagnostic tests for COVID-19 at the scale public healthcare systems require, the healthcare market is packed with new opportunities for investors.
Thermo Fisher (NYSE: TMO) and Roche (OTC: RHHBY) are two leading conglomerates benefiting from the increasingly dynamic coronavirus market by producing diagnostic tests for COVID-19. Investors seeking growth have a difficult decision to make. Both organizations responded promptly to the pandemic by developing and launching new products, initiating new collaborations, and acquiring promising companies to fuel future efforts. But does one of these competitors have a clear edge over the other in the context of the fight against COVID-19?
Source Fool.com
